Recent paradigm shifts in molecular cardiac imaging: establishing precision cardiology through novel 18F-labeled PET radiotracers by Werner, Rudolf A. et al.
Trends in Cardiovascular Medicine 30 (2020) 11–19 
Contents lists available at ScienceDirect 
Trends in Cardiovascular Medicine 
journal homepage: www.elsevier.com/locate/tcm 
Recent paradigm shifts in molecular cardiac imaging—Establishing 
precision cardiology through novel 18 F-lab ele d PET radiotracers  
Rudolf A. Werner a , b , c , Xinyu Chen b , c , Steven P. Rowe a , Constantin Lapa b , 
Mehrbod S. Javadi a , Takahiro Higuchi b , c , d , ∗
a Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University 
School of Medicine, Baltimore, MD, United States 
b Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany 
c Comprehensive Heart Failure Center, University Hospital Wuerzburg, Wuerzburg, Germany 
d Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 




Single-photon emission computed 
tomography 
Positron emission tomography 








a b s t r a c t 
In nuclear cardiology, numerous single-photon emission computed tomography radiotracers have been 
advocated to reflect various cardiac metabolic and functional conditions, but positron emission tomogra- 
phy (PET) may offer a more thorough evaluation, mainly due to superior characteristics associated with 
the latter imaging modality. This shift in recent years has been fueled by the introduction of 18 F-labeled 
PET radiotracers. Due to physical and chemical key properties, these imaging agents allow for more flex- 
ibility of imaging protocols and a better employment in the clinic. Potentially rendering perfusion, vi- 
ability, innervation and inflammation, 18 F-labeled PET radiotracers may truly pave the way for a global 
assessment of the current metabolic and functional status of the heart, e.g. after acute myocardial in- 
farction or for progressed heart failure. The present review aims to provide a precise overview of those 
recently introduced 18 F-labeled cardiac imaging agents and how those state-of-the-art, top-tier radiotrac- 
ers may redefine precision medicine in cardiology. 
© 2019 The Author(s). Published by Elsevier Inc. 
This is an open access article under the CC BY-NC-ND license. 































Recent years have witnessed a paradigm shift in cardiac molec-
lar imaging, in particular from single-photon emission computed
omography (SPECT) towards positron emission tomography (PET)
or numerous clinical applications [1–4] . However, short-half-live
adiotracers in nuclear cardiology limit the more widespread adop-
ion of PET, e.g. by the use of ultra-short half-life imaging agents
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 0 min) [5,6] . Thus, a great deal of progress has been made
y the introduction of 18 F-labeled imaging probes. Their long
alf-life of 110 min allow for a.) the use of dispatch systems (for
elivery from central cyclotron facilities), b.) the injection of a
ower amount of radioactivtiy (due to a higher positron yield), c.)
igh spatial resolution (due to a short positron range) and d.) de-
ayed imaging protocols [7] . In addition, PET agents may bene-
t from the introduction of fluoride, which in turn increases the
tability of a radiopharmaceutical ( Table 1 ) [7] . In light of mul-
iple potential pathophysiologies that result in heart failure (HF)
long with the wide armamentarium of different treatment op-
ions, an expert consensus panel recently proposed a “diamond”
pproach in the treatment of cardiovascular diseases, i.e. person-
lized assessments instead of a “one-size-fits-all” therapeutic con-
ept [8] . Notably, cardiac PET radiotracers labeled with 18 F target a
ide array of different cardiac metabolic conditions and functions.
pecifically, these include, but are not limited to: (I.) myocardial
erfusion, (II.) viability, (III.) innervation, and (IV.) inflammation
3,7,9,10] . The promising physical and chemical properties of 18 F-
abeled radiotracers may lay the proper groundwork to target those
arious pathological conditions in the failing heart, which in turnunder the CC BY-NC-ND license. 
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Table 1 
Advantages of 18 F-radiochemistry. 18 F-FDG = 2-deoxy-2- 18 F-fluoro-D-glucose. 
Property Resulting advantage 
Physical Long half-life of 110 min 
√ 
More flexibility in the study design [31] √ 
Use of dispatch system, which enables delivery from central cyclotron facilities to smaller PET imaging centers 
(proven to be cost-effective for the most commonly used radiotracer in oncology, 18 F-FDG) [7,12] √ 
Allows for physical exercise stress testing outside of the PET device (shorter half-life PET agents allow only for 
stress imaging under pharmacological stress) [3] 
Short positron range 
√ 
Enables higher spatio-temporal resolution in tissue [3] 
Lower positron energy 
√ 
Allows for the injection of less radioactivity [52] 
Chemical Fluoride Introduction 
√ 
Increases the stability of a radiopharmaceutical against metabolism at sensitive positions [7] √ 
Higher selectivity towards specific targets [7] √ 



































































































a  may contribute to such a “diamond” approach of tailoring treat-
ment regimens. In addition, such radiotracers could be available at
reasonable prices, as the long half-life of 18 F permits delivery of
unit doses from a regional cyclotron to external PET imaging cen-
ters [11] . This strategy has already been proven to be cost-effective
for the most commonly used imaging probe in oncology, namely
2-deoxy-2- 18 F-fluoro-D-glucose ( 18 F-FDG) [12] . In the present re-
view, we aim to provide a precise overview of such 18 F-labeled
cardiac radiotracers, which enables identifying the different etiolo-
gies in HF. Striving for a global assessment of cardiac functions
including perfusion, viability, innervation and inflammation, those
imaging agents may establish precision medicine in cardiology and
guide the cardiologist in making the appropriate diagnosis early
and accurately. 
Myocardial perfusion 
An integrative assessment of both myocardial perfusion and vi-
ability are of utmost importance to draw meaningful conclusions
on either scar tissue or hibernating myocardium in patients suffer-
ing from myocardial infarction (MI) [13] . Several SPECT myocardial
perfusion imaging (MPI) radiotracers have been advocated to al-
low for a reliable reflection of the current perfusion status of the
heart [14] , but PET MPI offers 3-dimensional capability along with
CT-based attenuation correction, increased spatio-temporal resolu-
tion and reliable quantification of absolute myocardial blood flow
(MBF) [2,7] . In particular, with 18 F-labeled MPI radiotracers, exer-
cise stress testing outside the scanner is feasible, which cannot
be implemented in the clinic with other short half-life PET MPI
imaging agents [3] . In the last decade, two 18 F-labeled radiotrac-
ers targeting mitochondria have been further evaluated. These are
the lipophilic cation 18 F-fluorobenzyltriphenyl-phosphonium ( 18 F-
FBnTP) and 18 F-flurpiridaz (previously referred as 18 F-BMS747158-
02), which has also been investigated in human [3] . Higuchi et al.
tested 18 F-flurpiridaz in a permanent and transient occlusion rat
model. After permanent ligation of the left coronary artery (LCA),
the defect size remained stable, while after transient ischemia
(3 min of LCA occlusion), 18 F-flurpiridaz redistributed to the in-
duced defect (i.e. tracer redistribution after reperfusion). Radio-
tracer reinjection further enhanced the normalization process [15] .
The concept of redistribution is based on underperfused but viable
myocardium, which retains the radiotracer while it washes out of
normal myocardial areas, i.e. initial defects appear to normalize
[16] . Thus, in this animal model of coronary occlusion, myocar-
dial viability has been assessed as well. Such an approach could
be the subject of future studies, e.g. by radiotracer injection under
physical stress with early and delayed imaging protocols, which
allows observation of such redistribution over the entire imag-
ing protocol. The same research group has also investigated 18 F-
FBnTP in a dedicated rat model of short-term occlusion and reper-
fusion. Notably, distinct characteristics of both 18 F-labeled MPI PET
radiotracers were observed: While 18 F-FBnTP demonstrated reten-ion stability over time, 18 F-flurpiridaz slowly restored the defect
rea ( Fig. 1 A) [17] . Altogether, the observed kinetics (redistribu-
ion after reperfusion) may allow for the use of 18 F-flurpiridaz in a
imilar way to clinical SPECT protocols (stress/rest 201 TI perfusion
rotocols) and for the assessment of myocardial viability [15,18] .
fter laying the proper groundwork in a preclinical setting, 18 F-
urpiridaz was subject to clinical trials in human. A phase 1 trial
emonstrated clear and homogenous myocardial uptake up to 5 h
ost-injection (liver clearance after 2 h): those findings are of rele-
ance, as the radiotracer is present in the myocardium to allow for
adiopharmaceutical administration at peak treadmill exercise [19] .
o assess the performance of 18 F-flurpiridaz for MBF assessment, 7
ealthy subjects with a low likelihood of myocardial ischemia and
 coronary artery disease (CAD) patients were enrolled. Lower MBF
n diseased vascular segments after adenosine stress was recorded
nd accompanied by a reduction in myocardial flow reserve (MFR),
hile subjects with no stress-inducible ischemia demonstrated no
uch findings [20] . A recent phase II trial underlined the promising
roperties of 18 F-flurpiridaz: In 143 subjects, both stress-rest PET
nd 99m Tc sestamibi SPECT were performed. First, the reader’s con-
dence in imaging interpretation was 20% higher for PET. Second,
 subcohort was also scheduled for invasive coronary angiography
ICA), serving as the gold standard. In patients with ICA proven
AD, the extent of the reversible defect assessed with PET was
arger than with SPECT ( Fig. 1 B) [21] . A recent phase III trial cor-
oborated the superior diagnostic accuracy of 18 F-flurpiridaz rela-
ive to SPECT MPI in CAD. Due to improvements in imaging quality,
bese subjects seemed to benefit from the use of the 18 F-labeled
adiotracer [22] . In a second phase III study (AURORA, ClinicalTri-
ls.gov Identifier: NCT03354273), patients will undergo both SPECT
nd 18 F-flurpiridaz PET MPI prior to ICA. In a head-to-head com-
arison, the diagnostic accuracy of both MPI modalities will be
ested to further determine the role of CAD detection with 18 F-
urpiridaz [23,24] . 
yocardial viability 
To date, the most widely used PET radiotracer for evaluat-
ng myocardial viability is 18 F-FDG. As a marker of glucose uti-
ization, it is taken up into the cardiomyocyte via glucose trans-
orters GLUT1 and 4, followed by a phosphorylation to 18 F-FDG-6-
hosphate (by hexokinase). Notably, phosphatase, which is needed
o convert 18 F-FDG-6-phosphate back to its original structure 18 F-
DG, is not available in the myocardium [13] . Thus, one may hy-
othesize that the increase of 18 F-FDG-6-phosphate precisely re-
ects the overall rate of GLUT transport and hexokinase activity.
ral glucose loading or co-infusion of insulin and glucose are rou-
inely employed in the clinic to improve diagnostic accuracy of
8 F-FDG PET. Myocardial uptake of 18 F-FDG increases due to en-
ogenous release of insulin and succeeding increased glucose
tilization along with inhibitory release effects of free fatty
cids from adipocytes [13] . As an underlying pathologic rationale,
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Fig. 1. (A) 18 F-labeled myocardial perfusion (MPI) positron emission tomography (PET) radiotracers in a rat model of short-term occlusion and reperfusion. 18 F-flurpiridaz 
and 18 F-fluorobenzyltriphenyl-phosphonium ( 18 F-FBnTP) were injected during ischemia. While 18 F-flurpiridaz demonstrated slow restoration of uptake, 18 F-FBnTP showed lack 
of washout [3] . This renders 18 F-flurpiridaz as a potential imaging agent for myocardial viability (stress/rest protocols similar to thallium 201). Modified from Higuchi et al. 
[15,17] © by the Society of Nuclear Medicine and Molecular Imaging, Inc. (B) FLUR PET and MIBI SPECT Images From an 82-Year-Old Man. The FLUR PET (top) and MIBI SPECT 
(bottom) images from an 82-year-old man with shortness of breath and an occluded native proximal left anterior descending (LAD) coronary artery and an occluded left 
internal mammary graft to the LAD and no other significant native CAD. The FLUR images show a severe reversible perfusion defect throughout the territory of the occluded 
proximal LAD, whereas the MIBI images show only a moderate perfusion defect in the distal LAD territory (apical slices). FLUR = flurpiridaz F 18; MIBI = Tc-99m sestamibi. 
Reprinted from the Journal of the American College of Cardiology (JACC), 61(4), Daniel S. Berman, Jamshid Maddahi, B. K. Tamarappoo, Johannes Czernin, Raymond Taillefer, 
James E. Udelson, C. Michael Gibson, Marybeth Devine, Joel Lazewatsky, Gajanan Bhat, Dana Washburn, Phase II safety and clinical comparison with single-photon emission 
computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography, 469-77, Copyright (2013), with 
























































d  schemic cardiomyopathy can be either associated with develop-
ent of myocardial scar (i.e. irreversible injury of cardiomyocytes)
r hibernating myocardium (i.e. temporary loss of the ability of
ontraction within an area of viable tissue) [13] . The latter con-
ition can be treated by an invasive revascularization procedure,
hich underpins the importance of a reliable segregation be-
ween irreversible vs. reversible cardiac injury. Thus, 18 F-FDG car-
iac imaging is routinely applied with MPI (either with SPECT
r PET radiotracers), as distinctive patterns of perfusion vs. via-
ility allow identifying potential candidates for catheter-based in-
erventions [13] . These are: (I.) preserved MP and viability, i.e.
ormal conditions, (II.) reduced MP vs. preserved viability, i.e. mis-
atch characterized by viable hibernation, (III.) both reduced, i.e.
 non-viable match and (IV.) preserved perfusion, but reduced glu-
ose metabolism in the heart, i.e. reversed mismatch pattern (al-
ered regional glucose metabolism) [13] . The second pattern in
 dual-tracer assessment reflects hibernating myocardium and is
ssociated with a remarkably better outcome. For instance, vom
ahl et al. showed that discordance of flow and metabolic status
ave a high predictive value for potential functional recovery af-
er revascularization in areas of varying degrees of reduced left
entricular ejection fraction (LVEF) [25] . The Recovery Following
evascularization-2 (PARR-2) trial further corroborated these find-
ngs in a randomized setting; patients diagnosed with ischemic
ardiomyopathy and higher degrees of mismatch ( > 7%) benefited
rom revascularization ( Fig. 2 ) [26] . Thus, such a dual-tracer as-
essment may guide the referring cardiologist towards an invasive
rocedure [13,26] . In addition, the Institute For Clinical Evaluative
ciences (ICES, Canada) concluded in an economic analysis that these of PET for the assessment of myocardial viability led to a re-
arkable cost reduction. The use of 18 F-FDG PET as a follow-up
ool led to a better 5-year survival rate and less cost compared
o thallium ( 201 TI) SPECT [27] . Apart from that, a reversed mis-
atch pattern (preserved perfusion vs. reduced glucose consump-
ion) has been linked to patients with left bundle branch block,
ost likely caused by alteration in the metabolic demand of glu-
ose in the septum [28] . Other potential factors include stunning
yocardium, e.g. reperfused MI or percutaneous coronary inter-
entions (PCI) followed by coronary vasospasm [29] . 
eurohumoral activation 
Neurohumoral conditions of the heart are routinely imaged
ith the SPECT radiotracer 123 I-meta-Iodobenzylguanidine ( 123 I-
IBG) [30] . As an underlying rationale on a subcellular level, those
eurohumoral radiotracers mimic physiological norepinephrine 
NE) turnover in the myocardium and thus reflect precisely
he current status of cardiac nerve integrity. Physiological NE
s stored in presynaptic vesicles and once a firing impulse has
rrived at the nerve terminal, NE is released into the synap-
ic cleft where it provokes further downstream cascades via
drenoreceptors located at the post-synapse [1] . Thereafter, NE is
nvolved in a recycling pathway via the presynaptical NE trans-
orter (NET, uptake-1), and is stored in presynaptic vesicles for
he next firing impulse. Radiolabeled NE analogues, also referred
o as “false neurotransmitters”, use the identical uptake-1 mech-
nism and thus, alterations in NE uptake correlate with either
ecreased radiotracer uptake or increased tracer washout [1] . In
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Fig. 2. Examples of Images and Reconstructed Polar Maps. (A) Perfusion (left) and F-18-fluorodeoxyglucose (FDG) (right) imaging in the short-axis (SA), vertical-long-axis 
(VLA), and horizontal-long-axis (HLA) planes. Reduced perfusion with predominately maintained FDG uptake (mismatch) is noted in the anterior, septal, and lateral walls of 
the left ventricle (LV). (B) Polar maps (scale is %): top row showing the raw perfusion (left) and raw FDG uptake (right) polar maps; middle row is the normalized perfusion 
defect and FDG defect; lowest row is the scar score (left) and mismatch score (right). Of the total LV myocardium, 8% was scar, and 20% was mismatch. The patient was 
referred for revascularization but died within 1 week, awaiting surgery. Reprinted from the Journal of the American College of Cardiology (JACC) Imaging, 2 [9] , Gianni 
D’Egidio, Graham Nichol, Kathryn A. Williams, Ann Guo Meng, Linda Garrard, Robert de Kemp, Terrence D. Ruddy, Jean DaSilva, Dennis Humen, Karen Y. Gulenchyn, Michael 
Freeman, Normand Racine, Francois Benard, Paul Hendry, Rob S. B. Beanlands, PARR-2 Investigators, Increasing Benefit From Revascularization Is Associated With Increasing 



































































a similar vein like for MPI, PET cardiac radiotracers have sev-
eral key advantages over SPECT, in particular for the assess-
ment of regional areas of denervated myocardium instead of a
global reflection of the entire heart, e.g. with 123 I-mIBG [31] .
Thus, recent years have witnessed a shift from neurohumoral
SPECT to PET radiotracers, e.g. with 11 C-hydroxyephedrine ( 11 C-
HED). However, the short half-life of the latter radiotracer lim-
its its more widespread adoption in the clinic and thus 18 F-
labeled radiotracers to assess loss of cardiac nervous function
are currently at the forefront to monitor cardiac nerve integrity.
These are N-[3-Bromo-4-(3-[18F]fluoro-propoxy)-benzyl]guanidine
( 18 F-LMI1195) as well as 18 F-Fluoro-Hydroxyphenethylguanidines
( 18 F-fluoro-3-hydroxyphenethylguanidine ( 18 F-4F-MHPG) and its
structural isomer 3- 18 F-fluoro-4-hydroxyphenethylguanidine ( 18 F-
3F-PHPG)) [1] . The most extensively investigated 18 F-labeled ra-
diotracer is 18 F-LMI1195. First, several in-vitro and in-vivo tests
confirmed the high specificity of this imaging agent towards
uptake-1, mainly by performing blocking studies with the potent
and selective uptake-1 blocker desipramine (DMI, a tricyclic an-
tidepressant) [31,32] . However, to further corroborate that 18 F-
LMI1195 closely mimics physiological NE turnover, this radiotracer
was also subject to studies investigating whether it is stably stored
inside presynaptic vesicles after being taken up via the presynap-
tic uptake-1. In an in-vivo head-to-head comparison using healthy
rabbits, the catecholamine analogue radiotracers 123 I-mIBG, 11 C-
HED and 18 F-LMI1195 were tested. Distinct radiotracer character-
istics were demonstrated: By using a DMI chase protocol (i.e.
DMI administered after tracer administration), retention kinetics of
the benzylguanidine-based radiotracers 123 I-mIBG and 18 F-LMI1195
remained stable, while 11 C-HED washout increased significantly.
Thus, being resistant to such a NET inhibitor chase protocol, it
can be concluded that 123 I-mIBG and 18 F-LMI1195 are stably stored
in presynaptic vesicles, while 11 C-HED undergoes a cycle of con-inuous release and reuptake through uptake-1 mechanism. Alto-
ether, 123 I-mIBG and 18 F-LMI1195 indeed closely mimic physio-
ogical NE, with the latter radiotracer having all the advantages of
ET technology ( Fig. 3 A–C) [31] . After laying the proper ground-
ork using dedicated animal and cell models, 18 F-LMI1195 was
ested in humans as well. In a phase I trial, the radiotracer showed
table and uniform myocardial activity up to 5 h post-injection
long with rapid blood clearance. Notably, an excellent heart-to-
iver ratio was demonstrated, which in turn allows for a precise
valuation of the inferior wall portion as well ( Fig. 3 D) [33] . In
 phase II trial, a head-to-head comparison of 18 F-LMI1195 and
1 C-HED was performed and a preliminary assessment in 9 par-
icipants revealed comparable findings in cardiac nerve integrity.
owever, 18 F-LMI1195 demonstrated superior diagnostic accuracy,
n particular for early cardiac imaging [34] . In light of these en-
ouraging results of both phase I/ II trials, a phase III trial is
nderway to establish the benefits of 18 F-LMI1195 in a clinical
etting, e.g. for risk stratification among HF, similar to its SPECT
ounterpart 123 I-mIBG [1] . 18 F-Fluoro-Hydroxyphenethylguanidines
 
18 F-4F-MHPG and 18 F-3F-PHPG) need complex kinetic (Patlak)
nalyses, but their underlying kinetic properties may allow for the
ssessment of even the slighest alterations in cardiac nervous func-
ion [35] . Notably, these agents have just recently been investigated
n human volunteers and a reproducible measurement of cardiac
erve function along with considerable low radiation exposure was
eported [36] . 
nflammatory activity 
In the last decades, several studies have proven the relevance
f 18 F-FDG for the assessment of inflammation in the myocardium.
or instance, it was recently demonstrated that longitudinal
8 F-FDG PET imaging has favorable properties to differentiate
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Fig. 3. (A) Averaged time activity curves and (B) representative short-axis images of in-vivo rabbit cardiac PET imaging. Desipramine (DMI) chase (i.e., DMI administered 
after tracer delivery) enhanced 11 C-Hydroxyephedrine ( 11 C-HED) tracer washout, while 18 F-N- [3-Bromo-4-(3- [18F]fluoro-propoxy)-benzyl]guanidine ( 18 F-LMI1195) washout 
remained stable. (C) Results of in-vivo rabbit 123 I-metaiodobenzylguanidine ( 123 I-mIBG) planar scintigraphy (SPECT) of the chest. Dotted lines indicate regions of interest in 
both heart and mediastinum. Similar to 18 F-LMI1195, DMI chase did not change cardiac distribution of 123 I-mIBG. This indicates stable storage inside the nerve terminal 
independent of norepinephrine (NE) transporter activity after initial transport. Thus, 18 F-LMI1195 indeed closely mimics physiological NE turnover at the sympathetic nerve 
terminal. Notably, 18 F-LMI1195 inherits all advantages of PET technology, along with the key properties of an 18 F radionuclide, such as superior imaging quality compared to 
short-living PET radioisotopes like 11 C-HED. Apart from that, all tested tracers ( 18 F-LMI1195, 11 C-HED and 123 I-MIBG) had a high affinity for neural uptake as demonstrated 
by the DMI blockade (DMI block, i.e. pretreatment of DMI prior to radiotracer injection, B and C). Modified from Werner et al. [31] © by the Society of Nuclear Medicine and 
Molecular Imaging, Inc and from Werner et al. [1] . (D) Representative sequences of whole-body 18 F-LMI1195 images in healthy volunteers 10 min and 5 h post-injection. A 
clear delineation of the heart along with low liver and lung uptake can be appreciated, in particular at the late imaging time-point. Modified from Sinusas et al., [33] © by 

































o  etween active from postinflammatory reaction. In a dedicated rat
utoimmune myocarditis model, myocarditis rats revealed a tem-
oral increase in 18 F-FDG uptake (peaked at week 3), which was
ollowed by a rapid decline thereafter. First, a close correlation
etween macrophage infiltration (assessed by CD68 derived from
xtracted hearts) and 18 F-FDG uptake was shown. Moreover,
uided by longitudinal 18 F-FDG imaging, an exchange of the adhe-
ive molecules CD44 (acute inflammatory marker) and CD34 (post-
nflammation marker) was demonstrated: CD44 positivity was
rimarily observed at tissue samples obtained at acute phase
i.e. at peak 18 F-FDG uptake), while CD34-positive staining areas
ere predominantly identified in samples harvested at both sub-
cute and chronic phases (i.e. at 18 F-FDG decrease) [10] . Thus,
8 F-FDG may hold the promise to distinguish between acute and
ost-inflammatory reaction, which in turn allows for PET-guided
ndomyocardial biopsies in myocarditis or tailored treatmenttrategies, e.g. by escalating immunosuppressive therapy at the
ight time ( Fig. 4 A–D). The capability of 18 F-FDG for a direct in-
errogation of infiltrating immune cells on a subcellular level has
lso been proven in a human setting by using PET-guided biop-
ies in subjects with clinically suspected active myocarditis [37] .
n a similar vein, response assessment to prednisolone with 18 F-
DG was also performed in a small cohort suffering from Takayasu
rteritis [38] . Rischpler et al. investigated 49 patients with ST-
egment elevation MI to explore the prognostic value of 18 F-FDG
ET in combination with magnetic resonance imaging (MRI) in a
rospective setting. An 18 F-FDG PET/MRI five days after PCI was
ollowed by a succeeding cardiac MRI 6–9 months later. First,
he extent of the 18 F-FDG signal and circulating leukocytes to pe-
ipheral blood (measured by CD14high/ CD16 + monocytes) corre-
ated significantly with the infarction size. Second, the intensity
f the 18 F-FDG signal was also associated with MRI-derived LV
16 R.A. Werner, X. Chen and S.P. Rowe et al. / Trends in Cardiovascular Medicine 30 (2020) 11–19 
Fig. 4. Exchange of adhesion molecules CD34 and CD44, guided by longitudinal in-vivo 18 F-FDG PET imaging in a rat model of autoimmune myocarditis. (A) At acute phase 
(3 weeks after immunization), a peak 18 F-FDG uptake was recorded, with corresponding CD44 positive stained myocardial areas. (B) At subacute phase (5 weeks post- 
immunization) and (C) chronic phase (10 weeks post-immunization), PET revealed a decline of cardiac tracer uptake: An increase in CD34 positivity was noted, whereas a 
further decrease of CD44 positively stained cells could be identified. (D) Quantitative analysis of adhesion markers at different phases revealed a low CD34 and – conversely 
– an increased CD44 positivity (in%) at acute phase. At both subacute and chronic phases, opposite findings with CD34 positively stained areas and a further decrease in 
CD44 positivity were recorded. Modified from Werner et al. [10] . This paper has been published in the European Heart Journal Cardiovascular Imaging. The version of record 
"Werner RA, Wakabayashi H, Bauer J, Schu ̈tz C, Zechmeister C, Hayakawa N, Javadi MS, Lapa C, Jahns R, Ergün V, Jahns V, Higuchi T; Longitudinal 18F-FDG PET Imaging in a 












































global and functional outcome measures, which was not depen-
dent on infarct size or monocytes: In a multivariable analysis, only
the 18 F-FDG-based mean standardized uptake value served as an
independent marker for LV outcome. Integrating these available
data, this novel imaging-guided concept may open avenues to vi-
sualize immune cell migration to the myocardium and identify pa-
tients most at risk for developing HF after MI. Most importantly,
18 F-FDG PET may even guide immunomodulatory therapies once
those have been added to the armamentarium of treatment op-
tions in HF [39] . Further studies, which allow segregation between
different myocardial inflammatory diseases based on 18 F-FDG
PET, are warranted, e.g. by investigating uptake patterns/signaling,
imaging timepoints or radiotracer dosing/kinetics among patients
suffering from different cardiac diseases (such as MI vs. myocardi-
tis). However, it has been hypothesized that other more leukocyte-
specific radiotracers than 18 F-FDG may allow for a more thorough
evaluation of inflammation in the myocardium [10] . For instance,
Thackeray et al. have recently tested the novel 18 F-labeled PET
imaging agent 18 F-flutriciclamide ( 18 F-GE180). This radiotracer tar-
gets the mitochondrial translocator protein (TSPO), which is pre-
dominantly overexpressed on activated macrophages [40] . In anlegant way, the authors assessed the impact of MI on cardiac and
rain inflammation hypothesizing a potential systemic interaction.
n an acute MI model in mice, the early TSPO signal predicted sub-
equent LV remodeling at week 8, paralleled by an elevated TSPO
ignal in the brain at week 1. Notably, progressive HF after MI
aused a second wave of neuroinflammation and treatment with
ngiotensin-converting enzyme inhibitors led to marked reduction
f acute inflammatory activity both in the heart and the brain (ac-
ompanied by improvement in cardiac function). Those findings
ere further corroborated in humans: compared to controls, an el-
vation of TSPO was noted in the infarct area that was paralleled
y neuroinflammation. Thus, defining a potential reciprocable in-
olvement of the heart-brain axis, the authors concluded that the
rain seems to be susceptible to acute MI, which in turn may en-
ble more embracing treatment concepts for both the heart and
he brain [40] . Kashiyama et al. also reported on the use of another
8 F-labeled radioligand for TSPO imaging, namely N,N-diethyl-2-[4-
2-fluoroethoxy) phenyl]-5,7-dimethylpyrazolo [1,5-a]pyrimidine-3-
cetamide (DPA-714). It was proven that 18 F-DPA-714 visualizes
acrophages-mediated immune rejection of transplanted iPSC-
erived cardiomyocytes of allogeneic origin [41] . 
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Table 2 
Overview of different 18 F-labeled radiotracers targeting various cardiac subcellular mechanism. 18 F-FBnTP = 18 F-fluorobenzyltriphenyl-phosphonium, SPECT = single photon 
emission computed tomography, PET = positron emission tomography, FDA = U.S. Food and Drug Administration, 18 F-FDG = 2-deoxy-2- 18 F-fluoro- d -glucose, GLUT = glucose 
transporter, PARR-2 = Recovery Following Revascularization-2, 18 F-LMI1195 = N-[3-Bromo-4-(3- [18F]fluoro-propoxy)-benzyl]guanidine, NET = norepinephrine transporter, 11 C- 
HED = 11 C-hydroxyephedrine, 18 F-4F-MHPG = 18 F-fluoro-3-hydroxyphenethylguanidine, 18 F-3F-PHPG = 3- 18 F-fluoro-4-hydroxyphenethylguanidine, MI = myocardial infarction, 
HF = heart failure, 18 F-GE180 = 18 F-flutriciclamide, 18 F-DPA-714 = N,N-diethyl-2- [4-(2-fluoroethoxy) phenyl]-5,7-dimethylpyrazolo [1,5-a]pyrimidine-3-acetamide. 
Targeting Radio-tracer Subcellular mechanism Key characteristics Clinical use and current trial status 
Myocardial 
perfusion 
18 F-flurpiridaz Mitochondrial 
complex I 
√ 
Demonstrated tracer redistribution after reperfusion, 
i.e. myocardial viability can be assessed [15] 
√ 
No clinical routine use, but a Special 
Protocol Assessment has been granted 
by the FDA [53] √ 
May allow for the use of 18 F-flurpiridaz in a similar 
way to clinical SPECT protocols (stress/rest 201 TI 
perfusion protocols) [15] 
√ 
Currently being investigated in a 
phase III study 
√ 
Phase I/ II trials: Extent of the reversible defect 
assessed with PET was larger than with SPECT and 
higher reader’s confidence in interpretation with 
18 F-flurpiridaz was noted [19,21] 




Primarily used in a preclinical setting [17] 
√ 




18 F-FDG GLUT transport and 
hexokinase activity 
√ 
Routinely employed in the clinic to assess potential 
mismatch between perfusion and viability (detection 
of potential hibernating myocardium) [13] 
√ 
FDA approved, in clinical routine use 
√ 
PARR-2 trial: patients diagnosed with ischemic 
cardiomyopathy and higher degrees of 
perfusion/viability mismatch ( > 7%) had a benefit 
from revascularization [26] √ 
Remarkable cost reduction compared to 201 TI SPECT 








Demonstrated excellent key properties closely 
mimicking physiological norepinephrine turnover 
[31,32] 
√ 
No clinical routine use, no FDA 
approval 
√ 
Phase I trial showed stable myocardial activity up to 
5 h post-injection and a radiation dose comparable 
to other PET radiotracers [33] √ 
Phase II trial: head-to-head comparison of 
18 F-LMI1195 and 11 C-HED, with 18 F-LMI1195 having 
superior diagnostic accuracy, in particular for early 
cardiac imaging [34] 
√ 




Need Patlak analyses and their kinetic properties 
may allow for the assessment of even the slighest 
alterations in cardiac nervous function [35] 
√ 
No clinical routine use, no FDA 
approval 
√ 
First in-human evaluations showed excellent 
imaging quality along with reproducible 
measurements of cardiac nerve function and a slow 
NET rate [36] 
Inflammation 18 F-FDG Macrophages, cell 
migration 
√ 
Visualized immune cell migration to the 
myocardium post-MI and may identify patients at 
risk for progressed HF [39] 
√ 
FDA approved, in clinical routine use 
√ 
Differentiated between acute and post-inflammatory 
reaction in myocarditis [10] √ 
Monitored immuno-modulatory treatment response 
in patients suffering from cardiac inflammation [38] 
18 F-GE180 Mitochondrial 
translocator protein 
√ 
Revealed systemic interaction between heart and 
brain after MI [40] 
√ 




Visualized macrophages-mediated immune rejection 
of transplanted iPSC-derived cardiomyocytes [41] 
√ 




























h  Table 2 summarizes the herein reviewed 18 F-labeled imaging
gents for myocardial perfusion, viability, innervation and inflam-
ation. 
uture perspectives 
edefining fractional flow reserve for coronary revascularization 
In two recent randomized trials (Fractional Flow Reserve ver-
us Angiography for Multivessel Evaluation, FAME and FAME-2), a
ractional flow reserve (FFR) cut-off value of 0.8 confirmed that the
se of FFR can be used to guide the referring cardiologist towards
oronary revascularization [42,43] . Notably, this threshold was
riginally introduced by noninvasive stress testing, e.g. by 201 TI
PECT [44] . Consequently, FFR has also been recently implemented
n current guidelines for patients with ischemic heart disease andhus such quantitative metrics assessed by MPI SPECT and PET hold
he promise of contributing to personalized medicine in cardiology
45,46] . Nonetheless, FFR can also lead to false-positive discover-
es in the presence of microvascular dysfunction or disease [46,47] .
hus, given the superior imaging characteristics of 18 F-labeled PET
PI radiotracers compared to SPECT or other PET MPI competitors,
t is possible that these novel radiotracers may redefine current
FR thresholds. 
mpact on clinical decision making and cost-effectiveness 
In a prospective, multicenter setting, Udelson et al. have shown
hat the use of SPECT agents reduces unnecessary hospitaliza-
ions among patients without acute ischemia by 10% compared
o those subjects evaluated with standard care [48] . Siegrist et al.
ave attempted the cost savings on cardiac treatment procedures
















































































































using the short half-life PET MPI radiotracer 13 N-ammonia: In the
vast majority of the patients having a high prevalence of known
CAD, treatment strategies were altered based on PET imaging find-
ings. Notably, a cost-effectiveness analysis also showed that PET
MPI led to a cost reduction of > 200 € per patient [49] . In light
of the superior imaging properties of 18 F-labeled MPI radiotracers
compared to other common SPECT or PET MPI imaging agents,
agents like 18 F-flurpiridaz may have an even more significant im-
pact on clinical decision making. Thus, future studies should de-
termine if these 18 F-labeled radiotracers affect the management in
CAD patients, if such altered treatment strategies will be imple-
mented by the referring clinicians or if hospital (re)admissions can
be avoided. 
Triple tracer approaches for a global assessment of cardiac function 
The concept of myocardial viability assessment in nuclear car-
diology is closely linked to myocardial perfusion [13] . Different
patterns of glucose metabolism, mainly derived by 18 F-FDG, along
with perfusion status guide the referring cardiologists towards
revascularization, e.g. for hibernating myocardium [13] . However, it
has been recently demonstrated that the area of denervation post-
MI exceeded the region defined by MPI: In a transient ischemia rat
model (LCA occlusion followed by reperfusion), the extent of den-
ervated myocardium (measured by 11 C-HED) was larger compared
to the perfusion defect area assessed with 201 TI [50] . Integrating
these information, a triple 18 F-labeled radiotracer approach for ren-
dering the viability/perfusion/cardiac nerve status may truly mirror
a global assessment of current conditions in the failing heart. Apart
from that, those radiotracers for measuring cardiac nerve integrity
can also be applied to a large variety of other diseases, e.g. in dia-
betes or in patients at risk for cardiac arrhythmic events [51] . 
Conclusions 
Several SPECT radiotracers have been advocated to reflect vari-
ous cardiac conditions, but PET may offer a more thorough eval-
uation of the myocardium, mainly due to the superior imaging
properties associated with the latter imaging modality. This shift
in recent years has been fueled by the introduction of 18 F-labeled
PET cardiac radiotracers. Given their multiple physical and chem-
ical key advantages over other PET probes, those imaging agents
allow for more flexibility in the study design and a better em-
ployment in the clinic. Potentially rendering the perfusion, viabil-
ity, innervation and inflammation of the myocardium, 18 F-labeled
PET radiotracers truly pave the way for a global assessment of the
current status of the heart, which in turn may be helpful to initi-
ate the appropriate treatment at the right time. Thus, beyond cur-
rent assessments of perfusion/viability, future effort s may turn to-
wards triple-tracer approaches using those long-living radiotracers,
e.g. by performing an additional 18 F cardiac nerve PET scan. More-
over, cost-effective analysis on 18 F-FDG PET for the assessment of
myocardial viability have already proven a significant impact on
cost savings in cardiology and thus, similar studies should be per-
formed to determine if implementation of other 18 F-labeled agents,
e.g. for MPI, may also lead to substantial savings. 
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